Alterations of the gustatory circuit underly taste disturbances after lesional tremor therapy with MRgFUS
Objective: Identification of structural brain alterations in patients with essential tremor (ET) reporting taste disturbances after magnetic resonance-guided focused ultrasound (MRgFUS) treatment. Background: Paraesthesias and…IMPACT OF COVID 19 ON PARKINSON’S DISEASE: A CROSS SECTIONAL STUDY
Objective: To review the impact of Covid 19 on symptoms and signs of Parkinsons as well as general being in patients with Parkinson’s Disease at…Correlation between 3 Tesla Brain MRI Nigrosome-1 imaging and SPECT 123I-Ioflupane in parkinsonian disorders
Objective: To correlate nigrosome-1 (NG1) imaging and SPECT 123I-Ioflopane findings to determine the feasibility and diagnostic value of NG1 imaging in a real-world clinical setting.…Impact on non-motor symptoms, cognition, and QoL after 1-year of DBS for Parkinson’s Disease: An interim report from the ADROIT NAPA sub-study
Objective: To present the impact on cognition, quality of life, and non-motor symptoms after 1-year of DBS for Parkinson’s Disease through the ADROIT post-market study.…A Week in the Life with Parkinson’s Disease: A Holistic Overview from Four Digital Technologies
Objective: To showcase a day in the life of a person with Parkinson’s disease (PD) using four multimodal digital technologies. Background: Assessments of PD are…White matter microstructural differences between essential tremor and Parkinson’s disease evaluated using advanced MRI biomarkers
Objective: To study white matter differences between essential tremor (ET) and Parkinson’s disease (PD) using standard diffusion tensor magnetic resonance imaging (DTI) and fixel-based analysis.…GP2: Growing a research community in the Parkinson’s disease genetics field through training and networking
Objective: To establish a virtual ‘center of excellence’ with resources and expertise to serve the training needs of the Global Parkinson’s Genetics Program (GP2; www.gp2.org)…Estimating the Meaningful Within-Patient Change Threshold for the MDS-UPDRS Part III
Objective: To estimate the meaningful within-patient worsening threshold (MWPWT) of the Movement Disorders Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS Part III in early-stage Parkinson's disease…Safety and Tolerability of Apomorphine Sublingual Film and Subcutaneous Apomorphine for the Treatment of OFF Episodes in Parkinson’s Disease
Objective: Evaluate safety and tolerability of apomorphine sublingual film (SL-APO) vs subcutaneous apomorphine (SC-APO) for the treatment of OFF episodes in patients with Parkinson’s disease…Closing the gap: Increasing access to genetic testing and counseling for Hispanics through PD research
Objective: To report preliminary genetic findings of Hispanic participants from the PD GENEration Registry and GEN-EP Latino study. Background: The incidence of Parkinson disease across…
- « Previous Page
- 1
- …
- 366
- 367
- 368
- 369
- 370
- …
- 1554
- Next Page »